MECHANISTIC EFFECTS OF SEMAGLUTIDE ON KIDNEY DISEASE IN TYPE 2 DIABETES: THE REMODEL TRIAL

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/b43defcae578467cf7f3fcdd8c80dda5.pdf
MECHANISTIC EFFECTS OF SEMAGLUTIDE ON KIDNEY DISEASE IN TYPE 2 DIABETES: THE REMODEL TRIAL

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Katherine
Tuttle
Katherine Tuttle Katherine.Tuttle@providence.org Providence Medical Research Center Providence Inland Northwest Health Spokane United States * University of Washington School of Medicine Kidney Research Institute and Nephrology Division Seattle United States
Petter Bjornstad pettermb@uw.edu University of Washington Medicine Diabetes Institute Division of Metabolism, Endocrinology and Nutrition, Department of Medicine Seattle United States - University of Washington Division of Endocrinology, Department of Pediatrics Seattle United States University of Colorado Anschutz Medical Campus Division of Renal Diseases and Hypertension, Department of Medicine and Department of Pediatrics Aurora United States
Menno Pruijm Menno.Pruijm@chuv.ch University Hospital of Lausanne and University of Lausanne Service of Nephrology Lausanne Switzerland -
Jeffrey Hodgin jhodgin@med.umich.edu University of Michigan Department of Pathology and Clinical Laboratories Michigan United States -
David Cherney David.Cherney@uhn.ca University Health Network Nephrology Division, Department of Medicine Toronto Canada -
Nicolas Belmar nlbn@novonordisk.com Novo Nordisk A/S Global Medical Affairs Søborg Denmark -
Milenta Chacko RZCH@novonordisk.com Novo Nordisk GBS India Biostatistics Bangalore India -
Vivek Das VVDA@novonordisk.com Novo Nordisk A/S Data Science Søborg Denmark -
Thomas Idorn thid@novonordisk.com Novo Nordisk A/S Medical and Science Søborg Denmark -
Philip Schytz PPSY@novonordisk.com Novo Nordisk A/S Medical and Science Søborg Denmark -
Matthias Kretzler kretzler@umich.edu University of Michigan Department of Internal Medicine and Bioinformatics Michigan United States -
-
-
-
-